LEADER 01643oam  2200481   450 
001 9910708376003321
005 20180221145754.0
035   $a(CKB)3460000000111867
035   $a(OCoLC)852784181$z(OCoLC)651846829$z(OCoLC)778279908$z(OCoLC)1011783160
035   $a(EXLCZ)993460000000111867
100   $a20130713d2002      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 13$aAn inquiry into the ImClone cancer-drug story $ehearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002
210  1$aWashington :$cU.S. Government Printing Office,$d2002.
215   $a1 online resource (iii, 759 pages) $cillustrations
300   $a"Serial No. 107-142."
320   $aIncludes bibliographical references.
517   $aInquiry into the ImClone cancer-drug story 
606   $aCetuximab$xTesting
606   $aDrugs$zUnited States$xTesting
606   $aInsider trading in securities$zUnited States
615  0$aCetuximab$xTesting.
615  0$aDrugs$xTesting.
615  0$aInsider trading in securities
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCO
801  2$bOCLCA
801  2$bOCLCQ
801  2$bOCLCO
801  2$bOCLCQ
801  2$bNJR
801  2$bGPO
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910708376003321
996   $aAn inquiry into the ImClone cancer-drug story$93523078
997   $aUNINA